123 related articles for article (PubMed ID: 36687151)
1. Data on 2D culture characterisation of potential markers in human HER2-positive breast cancer cell lines.
Pham SH; Griffiths LR; Okolicsanyi RK; Haupt LM
Data Brief; 2023 Feb; 46():108880. PubMed ID: 36687151
[TBL] [Abstract][Full Text] [Related]
2. Syndecan-4 regulates the HER2-positive breast cancer cell proliferation cells via CK19/AKT signalling.
Pham SH; Vuorinen SI; Arif KT; Griffiths LR; Okolicsanyi RK; Haupt LM
Biochimie; 2023 Apr; 207():49-61. PubMed ID: 36460206
[TBL] [Abstract][Full Text] [Related]
3. Syndecan-1 and -4 influence Wnt signaling and cell migration in human breast cancers.
Pham SH; Pratt K; Okolicsanyi RK; Oikari LE; Yu C; Peall IW; Arif KT; Chalmers TA; Gyimesi M; Griffiths LR; Haupt LM
Biochimie; 2022 Jul; 198():60-75. PubMed ID: 35183674
[TBL] [Abstract][Full Text] [Related]
4. Heparan sulfate proteoglycans play a dual role in regulating fibroblast growth factor-2 mitogenic activity in human breast cancer cells.
Delehedde M; Deudon E; Boilly B; Hondermarck H
Exp Cell Res; 1996 Dec; 229(2):398-406. PubMed ID: 8986623
[TBL] [Abstract][Full Text] [Related]
5. Heparan sulfate proteoglycans and human breast cancer epithelial cell tumorigenicity.
Okolicsanyi RK; van Wijnen AJ; Cool SM; Stein GS; Griffiths LR; Haupt LM
J Cell Biochem; 2014 May; 115(5):967-76. PubMed ID: 24357546
[TBL] [Abstract][Full Text] [Related]
6. Erythropoietin receptor expression and its relationship with trastuzumab response and resistance in HER2-positive breast cancer cells.
Zhang C; Duan X; Xu L; Ye J; Zhao J; Liu Y
Breast Cancer Res Treat; 2012 Dec; 136(3):739-48. PubMed ID: 23117856
[TBL] [Abstract][Full Text] [Related]
7. Heparan sulfate mediates trastuzumab effect in breast cancer cells.
Suarez ER; Paredes-Gamero EJ; Del Giglio A; Tersariol IL; Nader HB; Pinhal MA
BMC Cancer; 2013 Oct; 13():444. PubMed ID: 24083474
[TBL] [Abstract][Full Text] [Related]
8. The heparan sulfate sulfotransferase 3-OST3A (HS3ST3A) is a novel tumor regulator and a prognostic marker in breast cancer.
Mao X; Gauche C; Coughtrie MW; Bui C; Gulberti S; Merhi-Soussi F; Ramalanjaona N; Bertin-Jung I; Diot A; Dumas D; De Freitas Caires N; Thompson AM; Bourdon JC; Ouzzine M; Fournel-Gigleux S
Oncogene; 2016 Sep; 35(38):5043-55. PubMed ID: 27041583
[TBL] [Abstract][Full Text] [Related]
9. Overcoming trastuzumab resistance in HER2-overexpressing breast cancer cells by using a novel celecoxib-derived phosphoinositide-dependent kinase-1 inhibitor.
Tseng PH; Wang YC; Weng SC; Weng JR; Chen CS; Brueggemeier RW; Shapiro CL; Chen CY; Dunn SE; Pollak M; Chen CS
Mol Pharmacol; 2006 Nov; 70(5):1534-41. PubMed ID: 16887935
[TBL] [Abstract][Full Text] [Related]
10. The cell surface proteoglycan syndecan-1 mediates fibroblast growth factor-2 binding and activity.
Filla MS; Dam P; Rapraeger AC
J Cell Physiol; 1998 Mar; 174(3):310-21. PubMed ID: 9462693
[TBL] [Abstract][Full Text] [Related]
11. MDA-MB-134 breast carcinoma cells overexpress fibroblast growth factor (FGF) receptors and are growth-inhibited by FGF ligands.
McLeskey SW; Ding IY; Lippman ME; Kern FG
Cancer Res; 1994 Jan; 54(2):523-30. PubMed ID: 7506125
[TBL] [Abstract][Full Text] [Related]
12. Quantitative CK19 biomarker detection in breast cancer cell lines.
Orafa Z; Karimi N; Keyvani S; Oloomi M
J Med Life; 2022 Feb; 15(2):188-195. PubMed ID: 35419102
[TBL] [Abstract][Full Text] [Related]
13. Production of sulfated proteoglycans by human breast cancer cell lines: binding to fibroblast growth factor-2.
Delehedde M; Deudon E; Boilly B; Hondermarck H
J Cell Biochem; 1997 Mar; 64(4):605-17. PubMed ID: 9093910
[TBL] [Abstract][Full Text] [Related]
14. Androgen and fibroblast growth factor (FGF) regulation of FGF receptors in S115 mouse mammary tumor cells.
Ruohola JK; Valve EM; Vainikka S; Alitalo K; Härkönen PL
Endocrinology; 1995 May; 136(5):2179-88. PubMed ID: 7536664
[TBL] [Abstract][Full Text] [Related]
15. Glypican-1 is overexpressed in human breast cancer and modulates the mitogenic effects of multiple heparin-binding growth factors in breast cancer cells.
Matsuda K; Maruyama H; Guo F; Kleeff J; Itakura J; Matsumoto Y; Lander AD; Korc M
Cancer Res; 2001 Jul; 61(14):5562-9. PubMed ID: 11454708
[TBL] [Abstract][Full Text] [Related]
16. Obesity Suppresses Estrogen Receptor Beta Expression in Breast Cancer Cells via a HER2-Mediated Pathway.
Bowers LW; Wiese M; Brenner AJ; Rossi EL; Tekmal RR; Hursting SD; deGraffenried LA
PLoS One; 2015; 10(12):e0145452. PubMed ID: 26709918
[TBL] [Abstract][Full Text] [Related]
17. Syndecan-1 Promotes Angiogenesis in Triple-Negative Breast Cancer through the Prognostically Relevant Tissue Factor Pathway and Additional Angiogenic Routes.
Nassar E; Hassan N; El-Ghonaimy EA; Hassan H; Abdullah MS; Rottke TV; Kiesel L; Greve B; Ibrahim SA; Götte M
Cancers (Basel); 2021 May; 13(10):. PubMed ID: 34066023
[TBL] [Abstract][Full Text] [Related]
18. Regulation of fibroblast growth factor-2 activity by human ovarian cancer tumor endothelium.
Whitworth MK; Backen AC; Clamp AR; Wilson G; McVey R; Friedl A; Rapraeger AC; David G; McGown A; Slade RJ; Gallagher JT; Jayson GC
Clin Cancer Res; 2005 Jun; 11(12):4282-8. PubMed ID: 15958608
[TBL] [Abstract][Full Text] [Related]
19. Autocrine WNT signaling contributes to breast cancer cell proliferation via the canonical WNT pathway and EGFR transactivation.
Schlange T; Matsuda Y; Lienhard S; Huber A; Hynes NE
Breast Cancer Res; 2007; 9(5):R63. PubMed ID: 17897439
[TBL] [Abstract][Full Text] [Related]
20. Basal Protein Expression Is Associated With Worse Outcome and Trastuzamab Resistance in HER2+ Invasive Breast Cancer.
Chung A; Choi M; Han BC; Bose S; Zhang X; Medina-Kauwe L; Sims J; Murali R; Taguiam M; Varda M; Schiff R; Giuliano A; Cui X
Clin Breast Cancer; 2015 Dec; 15(6):448-457.e2. PubMed ID: 26248960
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
